Skip to main contentAI and Advanced
/
BALPHARMA · NSEMarket ticker unavailable · configure an authorised index feed
BA
NSE · Equity shares · Biotechnology & Drugs-0.20 · -0.19%
Bal Pharma BALPHARMA
NSE:INR 107.5
BSE:INR 88.5
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for BALPHARMA
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 107.7
Day rangeINR 107.07 — INR 115
52-week rangeINR 60 — INR 124.6
Volume1.08 L
Market cap139.03
P/E15.26
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)311.66
Net Income (INR Cr)6.28
Rev Growth (5 Year %)4.46
EPS Growth (5 Year %)3.41
P/E Ratio15.26
Book Value40.81
EPS3.95
Price/BV2.63Computed
Research path: Interpret Bal Pharma's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
BALPHARMABal Pharma1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 375.54 | 335.69 | 319.84 |
| Cash Equivalents | 7.21 | 8.05 | 13.29 |
| Other Liabilities Total | 12.17 | 7.39 | 6.91 |
| Long Term Debt | 31.88 | 31.4 | 36.35 |
| Common Stock Total | 15.92 | 15.92 | 15.8 |
| Other Current Assets Total | 40.01 | 25.49 | 24.17 |
| Total Assets | 375.54 | 335.69 | 319.84 |
| Current Portof LT Debt/Capital Leases | 127.63 | 11.67 | 7.49 |
| Total Equity | 82.23 | 77.42 | 72 |
| Long Term Investments | 8.07 | 7.13 | 2.67 |
| Retained Earnings(Accumulated Deficit) | 66.31 | 61.5 | 56.2 |
| Total Common Shares Outstanding | 1.59 | 1.59 | 1.58 |
| Tangible Book Valueper Share Common Eq | 40.81 | 38.69 | 35.94 |
| Goodwill Net | 3.83 | 3.83 | 3.83 |
| Total Liabilities | 293.31 | 258.27 | 247.83 |
| Total Debt | 159.52 | 150.38 | 139.6 |
| Short Term Investments | 3.72 | 3.75 | 7.77 |
| Cashand Short Term Investments | 10.93 | 11.8 | 21.06 |
| Total Receivables Net | 94.93 | 94.56 | 101.12 |
| Accounts Receivable-Trade Net | 93.63 | 92.44 | 99.62 |
| Property/Plant/Equipment Total-Net | 84.18 | 73.78 | 64.79 |
| Minority Interest | 0.03 | -0.01 | -0.03 |
| Total Current Liabilities | 249.23 | 219.5 | 203.06 |
| Total Inventory | 116.36 | 103.02 | 87.81 |
| Accounts Payable | 88.97 | 4.62 | 3.94 |
| Other Currentliabilities Total | 32.63 | 95.9 | 95.87 |
| Total Long Term Debt | 31.88 | 31.4 | 36.35 |
| Intangibles Net | 13.42 | 12 | 11.38 |
| Other Long Term Assets Total | 3.81 | 4.09 | 2.9 |
| Total Current Assets | 262.23 | 234.87 | 234.16 |
| Notes Payable/Short Term Debt | Not available | 107.31 | 95.76 |
| Deferred Income Tax | Not available | Not available | 1.55 |
| Note Receivable-Long Term | Not available | Not available | 0.12 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio0.66
Price to Sale Ratio0.45
Growth
Debt 5Yr CAGR %7.03
Margins
Operating Margin 12m6.68
Operating Margin 5y Avg6.01
Net Profit Margin 12m2.03
Net Profit Margin 5y1.91
Yield
Dividend Yield %1.34
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk49.31
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,935.8 | 4.64 L | 38.4 | — |
| Divi's Laboratories | INR 7,376.6 | 1.96 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,975 | 1.68 L | 72.73 | — |
| Cipla | INR 1,405.9 | 1.14 L | 27.57 | — |
| Zydus Lifesciences | INR 1,117.65 | 1.11 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 50.86%
- FII
- 0.15%
- Other
- 48.99%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Bal Pharma Ltd Valuation Improves as Price Attractiveness Shifts Amid Sector Challenges - MarketsMojoMarket news · 16 Jul 2026, 2:14 am
Bal Pharma Ltd Valuation Improves as Price Attractiveness Shifts Amid Sector Challenges MarketsMojo
Bal Pharma Ltd Upgraded to Hold as Technicals and Valuation Improve - MarketsMojoMarket news · 16 Jul 2026, 2:13 am
Bal Pharma Ltd Upgraded to Hold as Technicals and Valuation Improve MarketsMojo
Plastiblends India Reports Strong Q1 Performance, Net Profit Jumps 67% To ₹14.95 Crore On Higher Revenue - Free Press JournalMarket news · 13 Jul 2026, 6:27 pm
Plastiblends India Reports Strong Q1 Performance, Net Profit Jumps 67% To ₹14.95 Crore On Higher Revenue Free Press Journal
Bal Pharma seeks approval to issue warrants to promoter - scanx.tradeMarket news · 9 Jul 2026, 5:32 pm
Bal Pharma seeks approval to issue warrants to promoter scanx.trade
Stedman Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data - Revelio LabsMarket news · 9 Jul 2026, 6:14 am
Stedman Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data Revelio Labs
Bal Pharma Ltd Falls to 52-Week Low of Rs 64 as Sell-Off Deepens - MarketsMojoMarket news · 27 Jun 2026, 1:27 am
Bal Pharma Ltd Falls to 52-Week Low of Rs 64 as Sell-Off Deepens MarketsMojo
Corporate actions
Events
- annual General MeetingPOM
- dividendRs.1.2000 per share(12%)Final Dividend
- board MeetingsAudited Results, Final Dividend & ESOP
- board MeetingsQuarterly Results
- annual General MeetingPOM
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.1.2000 per share(12%)Dividend
Rusaka Markets Community
Discussion and sentiment for Bal Pharma
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Bal Pharma Limited is a pharmaceutical company engaged in the manufacturing and selling of pharmaceutical products. The Company is engaged in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (API). It specializes in prescription drugs, generic & OTC products, intravenous infusion, and bulk actives. The Company offers a range of APIs including antihistamine, platelet inhibitor, anti-diabetic, anticonvulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, acne treatment, and others. It also offers a range of formulations covering dosage forms-tablets, capsules, syrups, suspensions, IV infusions, ophthalmics, creams and ointments to various semi-regulated markets. The API products are being exported to Japan, Australia, Spain, the United Kingdom, Canada, Nigeria, Iceland, Slovenia, Romania, Brazil, Pakistan, Germany, South Africa, Serbia, Taiwan, Malaysia, Thailand, among others.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- BALPHARMA
- BSE Code
- 524824
Questions
Stock FAQ
What is the symbol and ISIN of Bal Pharma?
Bal Pharma has the symbol BALPHARMA and ISIN - INE083D01012.
What is the current price of Bal Pharma?
Bal Pharma is currently trading at INR 107.50.
What are the year high and year low of Bal Pharma?
Bal Pharma has a year high of INR 124.60 and a year low of INR 60.00.
What is the market capitalization of Bal Pharma?
Bal Pharma has a market capitalization of INR 139.03 crore.
What is the P/E ratio of Bal Pharma?
Bal Pharma has a P/E ratio of 15.26.
What is the dividend yield of Bal Pharma?
Bal Pharma has a dividend yield of 1.34%.
How is the financial performance of Bal Pharma based on revenue, net income, and EPS?
Bal Pharma has revenue of INR 311.66 crore, net income of INR 6.28 crore, and EPS of INR 3.96.
What is the book value of Bal Pharma?
Bal Pharma has a book value of INR 40.81.
What is the debt-to-equity ratio of Bal Pharma?
Bal Pharma has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Bal Pharma?
Bal Pharma has a price-to-book ratio of 2.63 and a price-to-sales ratio of 0.45.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.